Anthropic launched Claude Science in beta on June 30, 2026 — an AI workbench built for scientists that bundles more than 60 curated skills and connectors for genomics, single-cell analysis, proteomics, structural biology, and cheminformatics into one environment. The tool natively renders 3D protein structures, genome tracks, and chemical structures, automatically manages compute across local machines, HPC clusters, and on-demand GPUs, and pairs every run with a reviewer agent that checks citations and calculations for reproducibility.
Beyond selling software to researchers, Anthropic said it will become a drug developer itself, targeting neglected diseases that attract little commercial investment. To seed early adoption, the company is offering up to $30,000 in credits for as many as 50 "AI for Science" projects, with compute partner Modal kicking in up to $2,000 more per selected project; applications close July 15, 2026, with funded projects running from September through December.
Anthropic says early testers are already seeing dramatic gains — one genetics lab reported completing comprehensive germline workups in one-tenth the time previously required, with results independently validated. The launch signals AI labs moving from selling generic assistants to embedding directly in specialized scientific workflows, competing for a slice of the multi-billion-dollar drug discovery pipeline.